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Abstract
Phage therapy as a promising alternative antimicrobial to treat multidrug 
resistant (MDR) bacteria related lung infections, has drawn significant attention in 
clinical trials and bench-scale study in the recent decade, and the therapeutic effect 
of local delivery of phage has been demonstrated by several clinical reports. This 
book chapter discusses the current clinical development of inhaled phage therapy 
followed by the advancement of phage formulation designs for respiratory delivery 
of phage using various inhalation devices and their in vivo efficacy. The develop-
ment of combination therapy of phage and antibiotics to combat MDR bacteria 
associated lung infections is also covered to reflect the current clinical practice. 
Lastly, we also share our insights on the challenges of advancing inhaled phage 
therapy and potential directions for future research.
Keywords: pulmonary delivery, multidrug-resistant bacteria, respiratory infection, 
dry powder inhaler, nebulization, phage formulation, inhaled phage therapy
1. Introduction
Lung infection is a leading cause of morbidity and mortality worldwide [1]. 
Currently, antibiotics remain the mainstay treatment options for bacterial lung 
infections [2]. With the rapid emergence of multidrug-resistant (MDR) bacteria, 
last-line antibiotics such as colistin and carbapenem have been increasingly used 
for life-threatening infections. However, nosocomial outbreaks caused by pan-drug 
resistant (PDR) ‘superbugs’ have also been increasingly reported worldwide, creat-
ing significant therapeutic challenges for the treatment of lung infections [3–5].
Bacteriophage (phage) therapy has been proposed as a promising alternative to 
antibiotics in combating bacterial infections, including those caused by the MDR 
pathogens. A comprehensive review from Abedon summarized earlier clinical 
studies of phage application, with most reported cases from Eastern Europe as these 
countries more practical experience [6]. Overall, phage therapy for respiratory 
infections have not been extensively studied and only a handful of human studies 
reported [6–8].
Although recent failure of the “Phagoburn” trial against burn wound infec-
tions is discouraging, a lesson we learnt is the importance of the stability of phage 
preparations and the efficient delivery of sufficient amount of viable phage to the 
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site of infections [9]. Pulmonary delivery of phage would hold the greatest promise 
in achieving optimal concentration of phage in the lung for effective treatment. In 
this book chapter, we first introduce the clinical progress of inhaled phage therapy 
and highlight recent advancement made in the delivery of phage preparations using 
various inhalation devices. As most experimental phage therapeutic investiga-
tions were conducted with concomitant antibiotic treatment, we also discuss the 
development of phage-antibiotic combinations to treat lung infections. Lastly, we 
summarize the challenges that must be overcome in order to translate inhaled phage 
therapy to clinical applications.
2. Clinical development of inhaled phage therapy
In the past decade, a few success stories in experimental inhaled phage therapy 
were reported. Hoyle et al. reported a successful inhaled phage therapy to man-
age chronic lung infection caused by MDR Achromobacter xylosoxidans [10]. The 
17-year-old female patient was unsuccessfully treated with many rounds of antibi-
otics before she was given a phage cocktail treatment containing two Achromobacter 
phages in the Eliava Phage Therapy Center. The phage cocktail was given by nebu-
lization once daily and orally twice daily for 20 days. The treatment was repeated 
4 times at 1, 3, 6 and 12 months after the initial treatment. The patient’s subjective 
conditions were significantly improved and her lung function-FEV1 increased from 
1.83 L to 3.33 L together with intermittent antibiotic regimen. Successful phage 
treatment was also reported for a 12-year-old lung-transplanted cystic fibrosis 
(CF) patient suffered from persistent lung infection caused by PDR A. xylosoxidans 
[11]. After two rounds of inhaled phage therapy, the patient’s respiratory condition 
slowly improved and the bacterial load was significantly reduced. Similar favorable 
therapeutic efficacy was also reported in another clinical case [12], where a five-
year-old cystic fibrosis patient suffering from severe lung infections was treated 
with a commercially available phage preparation (pyophage) by nebulization.
Aslam et al. reported the early clinical experience of phage therapy in lung 
transplant recipients in the USA [13]. Three patients with life-threatening MDR 
infections caused by Pseudomonas aeruginosa (n = 2) and Burkholderia dolosa (n = 1) 
received phage cocktails via both intravenous injection and nebulization with 
concurrent antibiotic treatments for variable duration. Two patients responded 
clinically with the phage treatments and were discharged from hospitals, while the 
third patient infected by B. dolosa was dead due to infection relapsed. Nonetheless, 
no phage therapy-related adverse events were identified. While these experimental 
use of inhaled phage therapy as an adjunct treatment has demonstrated the clinical 
benefits in treating lung infections caused by MDR superbugs, well-designed clini-
cal trials are needed to convincingly evaluate its clinical efficacy.
To date, there have been three phage therapy clinical studies registered with 
the ClinicalTrials.gov to evaluate the safety and efficacy of phage therapy against 
lung infections (Table 1). “MUCOPHAGES” (NCT01818206) assessed the effect 
of a cocktail of 10 phages on P. aeruginosa from sputum samples isolated from CF 
patients. Although the trial was completed in 2012 according to the clinical trial 
registry, no information about the outcome of this trial was published. In 2020, 
two other trials were launched. One trial (NCT04636554) is attempting to apply 
personalized phage treatment in Covid-19 patients with bacterial co-infections 
microbial for pneumonia or bacteremia/septicemia. Another trial launched by 
Armata Pharmaceuticals is a Phase 1b/2a, double-blind, randomized, placebo-
controlled trial (NCT04596319) aiming to study the safety, tolerability, and pre-
liminary efficacy of inhaled AP-PA02 in subjects with CF and chronic pulmonary 
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P. aeruginosa infection. This is the first randomized trial on inhaled phage therapy 
and the AP-PA02 cocktail is an advanced version of AP-PA01 which was used in 
the successful experimental study documented in Aslam et al. [13]. The findings 




Majority of the phage studies for lung delivery focus on liquid formulations as 
minimal formulation development is required to prepare phage cocktails with suf-
ficient stability for a short storage period. The long term storage stability of phage in 
liquid formulations was often reported. Cooper et al. demonstrated a phage cocktail 
of 3 Pseudomonas phages (GL-1, GL-12.5 and LP-M10) suspended in phosphate 
buffered saline (PBS) was stable at both 4 °C and room temperature with no statis-
tically significant titer loss (≤ 0.5 log) for 6 months [14]. As most commonly used 
phage stabilizers, including PBS, salt-magnesium buffer (SMB) and Tris-H buffer 
are not yet approved for inhalation. Dilution of phage suspension with 0.9% sodium 
chloride (NaCl) is usually needed for pulmonary administration [10]. Carrigy et 
al. showed minimal impacts on the phage stability with the NaCl dilution process, 
suggesting the suitability of this approach [15].
To date, nebulization has been the exclusive choice for pulmonary delivery of 
phage suspension in human studies due to its high delivery efficiency and capability of 
delivering a large volume of liquid phage formulation (> 1 mL) to patients including 
those cannot administer the dose voluntarily. Several types of commercial nebulizers 
are available to aerosolize phage into fine droplets using different aerosol generation 
mechanisms, including air-jet nebulization, vibrating mesh nebulization, ultrasonic 
nebulization, and colliding liquid jets [16, 17]. The suitability of these nebulizers in 
delivering phage to lungs has been previously evaluated in terms of deactivation of 
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Jet nebulizers use compressed air to atomize the liquid phage suspension into 
primary droplets and their subsequent impaction onto the baffle would further 
breakdown into smaller droplets suitable for inhalation. LC-star nebulizer [16, 18], 
Collison 6-jet [19–21], LC Sprint jet nebulizer [22], AeroEclipse [23] and atomizer 
[24] have been used to deliver therapeutic phages. Leung et al. showed the air-jet 
nebulization had negligible impacts on the stability of the Podovidae PEV2 phage, 
while significant titer loss was found in Myoviridae PEV40 phage (~1 log loss) 
and Siphoviridae D29 phage (~3 log loss) [22]. Based on the cryo-transmission 
electron microscopy analysis, they found the nebulization-induced titer loss was 
correlated with morphological damage to phages. They further suggested that the 
length of phage tail may be an important consideration when delivering phages 
via jet nebulization, particularly for phage cocktails containing phages of different 
morphologies. The influence of the final formulation composition for nebulization 
of D29 phage was evaluated by Liu et al. using a Collison 6-jet nebulizer [19, 21]. 
They reported that deionized water was the optimal spray liquid for D29 aerosol 
generation and they postulated that the high ion strength and salt concentrations 
in the PBS and 0.9% NaCl were detrimental to the phage upon jet nebulization. 
These results were in accord with Carrigy et al. and Leung et al. nebulizing buffered 
D29 using other jet nebulizers [15, 22]. Liu et al. also studied the impact of relative 
humidity (RH) on the stability of nebulized D29 and found a low environmental 
humidity condition was more favorable for D29 nebulization [19]. Later, Verreault 
et al. reported that the stability of nebulized phage aerosols at different tempera-
tures and humidity is phage-dependent with some being more robust and some 
being more vulnerable [21]. Overall, these studies highlighted the importance of 
controlling the temperature and RH for phage nebulization.
Vibrating mesh nebulizers produce aerosol droplets by extruding the liquid for-
mulation through a membrane with calibrated holes based on the converse piezo-
electric effects. Several studies compared the aerosol delivery of phage between jet 
and mesh nebulizers [15, 16, 23–25]. Golshahi et al. showed both the LCstar (air-jet) 
and eFlow (mesh) nebulizers were suitable for the delivery of phages active against 
Burkholderia cepacia Complex by imaging the lung deposition and mathematical 
model prediction [16]. In some studies, mesh nebulizers were found to be more 
detrimental to phage than air-jet nebulizers [23, 24], but reasons for the poorer 
delivery of mesh nebulizer were unclear. In contrast, better phage recovery was 
noted after nebulizing using a mesh nebulizer compared with the jet nebulization 
in some other studies [15, 25]. Visual evidence on the correlation between the titer 
reduction and morphological change of a Myoviridae PEV44 phage after nebuliza-
tion was provided by Leung et al., showing more “intact” phage was detected in 
the mesh-nebulized phage samples under TEM image. The more destructive effect 
of jet nebulization is likely caused by stresses associated with the droplet produc-
tion and re-nebulization processes. Based on the collected experimental data and a 
mathematical model, Carrigy et al. estimated phage were re-nebulized an average 
of 96 times before exiting the mouthpiece of the jet nebulizer [15]. A review from 
Prichard et al. revealed that 86% of the disclosed nebulizer technology have chosen 
vibration-mesh nebulizers as the delivery devices, particularly for stress-sensitive 
drugs [26]. The mixed findings of phage nebulization in the literature can be 
attributed to many factors, such as phage types, formulation composition, experi-
mental conditions (like temperature, humidity and sample collection methods) and 
different models of the same nebulizer type. Therefore, the survival of individual 
phages within a cocktail should be tested with different delivery devices for the 
optimization of phage cocktail – inhalation device combinations.
Ultrasonic nebulizers use a piezoelectric transducer to generate ultrasonic wave 
in the liquid drug formulation and aerosolize it at the solution surface. Upon the 
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nebulization process, a portion of the ultrasonic energy converts to heat, which 
could be detrimental to heat-sensitive biologics, like phages. Only one study 
reported the use of an ultrasonic nebulizer to deliver phage to treat lung infections 
in a mink model, but little data on the nebulization process was available [27]. 
More recently, Marqus et al. assessed the capability of a novel low cost and portable 
hybrid surface and bulk acoustic wave (HYDRA) nebulizer to deliver a Myoviridae 
phage K and lysostaphin to target Staphylococcus aureus [28]. Negligible titer reduc-
tion was noted (0.1 log loss), possibly due to the relatively low powers and high 
frequencies (approximately 10 MHz) of the nebulizer. Furthermore, the size of the 
aerosols generated by HYDRA is smaller (DV50 1.85 μm), well within the respirable 
range, demonstrating its suitability for pulmonary delivery of phages.
3.2 In vivo efficacy of inhaled phage therapy achieved with nebulization
The in vivo efficacy of phage liquid formulation has been studied in rodent and 
mink models. Semler et al. established B. cenocepacia respiratory infection model 
in mice and then treated with liquid phage formulation delivered by a LC-star jet 
nebulizer or intraperitoneal injection (IP) [18]. After a 2-day treatment, the lung 
bacterial load was only reduced by ~0.5 log in mice received phage via IP injection, 
but a 2-log bacterial reduction was observed in mice treated with inhaled phage. 
This finding is in contradiction with a previous study showing that phage delivered 
by the IP route was more efficacious than intranasal instillation in treating a B. ceno-
cepacia respiratory infection in mice [29]. Semler et al. accounted the discrepancy to 
the efficiency of phage delivery to lungs that nebulization is a more effective way in 
delivering phage particles to the lung than intranasal instillation. Also, the capabil-
ity of IP injected phage reaching lung is significantly affected by the clearance rate 
of phage in blood which is phage-dependent. The in vivo delivery efficiency of D29 
phage using a Collison 6-jet nebulizer and IP route was compared by Liu et al. [20]. 
Approximately 10% of D29 phage could reach to the lung of mice after nebuliza-
tion and complete phage elimination was noted in 72 h, whereas only 0.1% of the 
phage could reach the lung by IP injection and no phage was detected after 12 h. The 
importance of phage dose on the pharmacokinetics/pharmacodynamics (PK/PD) 
of inhaled phage therapy was recently confirmed by Chow et al. using Pseudomonas 
phage PEV31 [30].
Carrigy et al. recently demonstrated the prophylactic function of nebulized 
D29 phage for protection against Mycobacterium tuberculosis infection in a mouse 
model [31]. Phage was delivered with a vibrating mesh nebulizer and a dose of 6.6 
log phage reached the lung and remained there for 90 min post-delivery, suggesting 
that phage was not rapidly cleared in the mouse lung. Low doses of M. tuberculosis 
(5–100 CFU) were given to mice 30 min post phage administration. This phage 
pretreatment was able to significantly reduce the bacterial burden in mouse lungs 
at 24 h and 3 weeks post infection. The prophylactic effect of phage was also 
demonstrated in a rat model against methicillin-resistant S. aureus infection [32]. 
Phage was given by a vibrating mesh nebulizer 4 h before the bacterial challenge, 
higher survival rate (60–70% improvement) with a 2 log bacterial reduction in the 
rat lungs were observed. Both studies demonstrated prophylactic treatment with 
sufficient dose of nebulized phage may provide protection to immunocompromised 
individuals and health care professionals who are at risk of exposure to “superbugs”.
There is accumulating evidence that bacterial clearance by phage therapy requires 
the synergy between phage and host immune system. Therefore, the translation of 
preclinical data collected from rodent to humans should be treated with care due to the 
significant difference in their immune systems [33]. Cao et al. explored the phage anti-
bacterial effect of hemorrhagic pneumonia in a mink model [27]. Effective treatment 
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outcomes were achieved at multiplicity of infection (MOI) of 10 with an 80% survival 
rate at 12 days after phage administrated by means of ultrasonic nebulization.
4. Dry powder inhalers
4.1 Powder formulation
Although nebulization has been the method of choice for phage delivery in 
treating lung infections in clinical settings, dry powder formulations are preferred 
to liquid formulations in terms of storage, transportation and administration [34]. 
Compared to nebulizers, dry powder inhalers (DPIs) are easier to handle without 
the need of a power source, fewer cleaning requirements and quick delivery [35]. 
Current research on pharmaceutical development of inhaled phage dry powder 
mainly focuses on formulation optimization for sufficient powder dispersibility to 
deliver phage to the lung and storage stability. The choice of excipients plays a key 
role among all the techniques to produce phage dry powder. Zhang et al. published a 
comprehensive review to discuss how the choice of excipients affecting the stability 
of phage in the solid-state [36]. Overall, sucrose, lactose and trehalose are the most 
popular disaccharides in phage powder formulations. Freeze drying (FD), spray 
drying (SD) and spray freeze drying (SFD) have been used to generate inhalable 
phage dry powders with these excipients.
FD is a commonly employed technique to stabilize drugs in solid state 
[37]. Puapermpoonsiri et al. used FD to generate dry powder of phage-loaded 
poly(lactic-co-glycolic acid) (PLGA) microspheres designed for pulmonary deliv-
ery [38]. Although phages were successfully incorporated into the PLGA micropar-
ticles, the poor shelf-life of the encapsulated phage which completely deactivated 
within 7 days either stored at 4 °C or 22 °C was discouraging. In their follow-up 
study, they investigated the feasibility of using a high concentration of sucrose 
(0.5 M) or PEG6000 (5%) to stabilize the FD phage cake [39]. Although rapid 
phage reduction was still noted over the first 7–14 days, phage remained relatively 
stable in the powder formulations thereafter. Since then, a number of studies have 
studied the impacts of various excipients on the production loss and storage stabil-
ity of FD phages [40–43]. Among all excipients examined, sucrose and trehalose 
were identified as the most promising stabilizers to preserve phage viability upon 
the dehydration in the drying process and upon storage. The residual moisture 
content was found to play an important role in maintaining phage stability. Similar 
to other protein therapeutics, a 3–6% moisture content of the powder cake was 
found to be optimal for phage preservation [39, 41]. Although the mechanisms of 
phage stabilization in dry powder by these sugars are still unclear. Two most accept-
able hypotheses for the stabilization of proteins in the solid state by sugars are water 
replacement and vitrification, which may also be applicable to phages because they 
are mostly composed of proteins.
In general, FD powder is not respirable, and a separate milling step is required 
to reduce the particle size to <5 μm, suitable for pulmonary delivery. However, the 
high-energy milling may cause additional phage loss due to the generation of heat 
and mechanical stresses. Golshahi et al. prepared FD formulations of KS4-M and 
ΦKZ phages with 60% lactose and 40% lactoferrin suitable for pulmonary delivery 
without milling [44]. The size of the phage powder was within the inhalable range 
(< 5 μm) and acceptable aerosol performance with a fine particle dose of >106 pfu 
using an Aerolizer was achieved. The production loss was 1–2 log which was not 
desirable, but the FD phage powders were stable with negligible titer reduction 
within 3 months storing either at 4 °C or 22 °C.
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SD is a well-established single-step technique employed for the production 
of many inhaled pharmaceutical products [45]. Matinkhoo et al. were among 
the first to study the feasibility of using SD to produce inhalable phage powders 
comprising trehalose and leucine with or without a third excipients (a surfactant 
or casein sodium salt) [46]. In these formulations, trehalose was used to protect 
phage against dehydration; leucine forming a crystalline shell at the particle surface 
was used to enhance the dispersibility of powders; and a surfactant was employed 
to reduce aggregation of phage during the drying process. Due to the thermal 
sensitivity of phage, a low drying temperature was used to produce SD powders 
with acceptable production loss (0.4–0.8 log) and phage lung dose (7–8 log pfu). 
Trehalose-alone formulation was employed by Vandenheuvel et al., but the pro-
duction loss was found to be phage dependent [47]. On the other hand, trehalose-
leucine and lactose-leucine systems could stabilize a panel of Pseudomonas phage 
upon the SD process [48–51]. Since the SD trehalose and lactose is amorphous, 
Chang et al. demonstrated that the addition of a sufficient amount of leucine (at 
least 20%) was critical to stabilize phage by minimizing recrystallization of treha-
lose/lactose during powder production process [48]. Despite a low production loss 
was achieved, particle merging was still significant for formulation containing 80% 
sugar and 20% leucine due to moisture sorption upon handling. Therefore, higher 
leucine content and the addition of mannitol to the excipient system was attempted 
to improve the morphology and reduce the moisture sorption capacity of the 
phage powders during handling and storage (Figure 1a-c) [49, 50]. Although these 
approaches significantly reduce the problem of particle merging and make powder 
handling easier, they failed to stop the recrystallization of the amorphous content 
at high humidity conditions (RH > 50%). Therefore, storing the SD powders at 
low humidity conditions (RH ≤ 20%) was generally recommended [48, 49, 52, 53]. 
The storage temperature was also reported to be important on phage dry powder 
stability. It is generally recommended to store phage drug powder at a temperature 
at least 50 °C below the glass transition temperature (Tg) of the powders [54]. 
Figure 1. 
Representative scanning electron microscopy images of phage powders produced by spray drying (a-c) and 
spray freeze drying (d). (a) 80% trehalose+20% leucine; (b) 60% trehalose +20% mannitol +20% leucine;  
(c) 70% trehalose +30% leucine and (d) 60% trehalose+20% mannitol and 20% leucine.
Bacteriophages
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Overall, SD phage powders composed of trehalose/lactose not less than 40% of the 
total solid content together with leucine and mannitol was able to stabilize phage in 
powder form with sufficient long shelf-life (≤ 1 log titer loss in 12 months) under 
refrigeration or room temperature at RH < 20% and yield acceptable lung dose 
(105–107 pfu) [46–50, 53]. While leucine is a commonly employed surface active 
agent to improve the powder dispersity of inhaled pharmaceuticals, trileucine has 
also been increasingly used to improve aerosol performance and stability of SD 
powders for inhalation. Recently, Carrigy et al. demonstrated the effectiveness of a 
trileucine and trehalose system in preserving an anti-Campylobacter phage, CP30A, 
in powder form for long-distance ambient temperature transportation [55, 56].
SFD is a relatively new drying technique to produce inhalable dry powders. 
The produced powders are superior to those prepared by traditional FD in terms 
of structure, quality, and the retention of volatiles and bioactive compounds [57]. 
The suitability of SFD porous mannitol carriers for pulmonary delivery of drug 
nanoparticles and biologics have been demonstrated [58–60]. Leung et al. produced 
SFD phage powder and compared their differences of powder properties with the 
SD phage powders (Figure 1d). With the use of a high frequency of ultrasonic 
nozzle in the SFD process, a significant titer reduction (>2 log) was noted in the 
spraying process, making the overall production loss inferior compared with the 
SD process [53]. Nonetheless, the larger porous carrier provided a larger extent of 
protection of the embedded phage during aerosolization with a higher recovery of 
viable phage compared with the SD counterparts. The conventional SFD process 
is a two-step manufacturing process, which hinders scaling up. Ly et al. used an 
atmospheric spray freeze-drying (ASFD) technique, which is a single step process, 
to prepare D29 phage powder [61]. An acceptable titer loss (~0.6 log) was noted due 
to the use of a twin-fluid nozzle and improved mass and heat transfer rates.
4.2 In vivo efficacy of inhalable phage dry powder
Pulmonary delivery of dry powder to small animals is challenging as they cannot 
inhale powder actively. Intratracheal delivery using a dry powder insufflator, either 
the commercially available Penn-Century models or custom-made insufflators [62], 
are commonly employed to introduce powders directly into the lungs of the experi-
mental animals. Chang et al. explored the in vivo efficacy of phage powder to treat 
lung infections caused by MDR P. aeruginosa in a mice pneumonia model [63]. After 
challenging the neutropenic mice with intratracheal administration of the bacterial 
suspension for 2 h, powder of phage PEV20 was administrated use a Penn-Century 
dry powder insufflator at a concentration of 2 × 107 pfu/mg. A significant bacterial 
reduction (5.3 log cfu) was noted after 24 h post-infection accompanies with 1 log 
phage propagation. The successful treatment outcomes and safety profile from this 
study warrant further investigation to fully evaluate the therapeutic potential of 
inhaled phage powder in managing lung infections.
5. Other inhalation devices
5.1 Metered dose inhaler
Pressurized metered-dose inhalers (pMDIs) are the most popular inhalers for 
the treatment of asthma and chronic obstructive pulmonary diseases. To date, only 
one study has attempted this type of device to aerosolize phage [64]. The phage 
cocktail suspension containing FKZ/D3 and KS4-M phages, was formulated in a 
reverse emulsion with Tyloxapol surfactant using hydrofluoroalkane 134a as the 
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propellant. A limited loss of phage activity (0.5–0.9 log) upon the actuation was 
observed, but the long term storage stability of the phages was not assessed. Further 
studies to examine the interactions between phage and liquefied propellant gas [65], 
and maximum loading capacity of phage/puff are required to move this inhaler 
choice forward.
5.2 Soft mist inhaler
Soft mist inhaler (SMI) is a relatively new generation, propellant-free inhaler 
that delivers drugs to the lung more efficiently than pMDIs because of the lower 
spray velocity and longer duration time [66]. Carrigy et al. compared the delivery 
efficiency of phage among vibrating mesh nebulizer, jet nebulizer and SMI [14]. 
SMI was showed to deliver phage D29 at high titers quickly (~5 × 108 pfu/actua-
tion) with an acceptable titer reduction (0.6 log pfu/ml) and a higher lung delivery 
(3.2 × 106 pfu/actuation of inhalable active phage). This compact and light weight 
device may act as an attractive option for self-administration of phage aerosols.
6. Combination of phage therapy and antibiotic to treat lung infections
6.1 Mechanisms of phage-antibiotic synergy
With the emergence of phage-resistant bacteria [67], the combination therapy 
of antibiotics and phages has drawn increasing attention. Synergistic effect 
of antibiotic and phage against S. aureus was first reported by Himmelweit et 
al. back in 1945 [68]. Similar synergistic antibacterial effects have also been 
observed in a number of subsequent studies [69–79]. In 2007, Comeau et al., 
coined the term phage-antibiotic synergy (PAS) corresponding to an incident 
where the killing effect of bacterial strains considerably higher when phage pro-
duction increases by the sublethal concentrations of particular antibiotics [80]. 
While many antibiotics exhibit synergistic effect in combination with phages, 
two specific classes of antibiotics (namely beta-lactams and fluoro-quinolones) 
were shown to produce a more consistent and pronounced antibacterial syner-
gistic effect with phage therapy. The precise mechanisms contributing to phage-
antibiotic synergy remain largely unknown. A few possible mechanisms have 
been proposed (Figure 2): (1) Antibiotic causes cell elongation or filamentation, 
thus subsequently promoting phage production; (2) Degradation of the extracel-
lular membrane of bacteria by phage facilitates internalization of antibiotic into 
cells; (3) Auto-aggregation of bacterial cells leads to synergism; (4) Bacteria 
containing complete prophages could be induced by antibiotics which further 
kill bacteria [81]. The capacity of phage in resensitizating bacteria to certain 
antibiotics have also been reported as the host bacteria cannot develop resistance 
to phage and antibiotic simultaneously [82–84]. As a result, the phage-antibiotic 
combination can kill both phage-sensitive and antibiotic-sensitive pathogens with 
the phage lysing cells resistant to antibiotics and antibiotic mediated killing of 
phage-resistant bacterial cells and eventually inhibit the infections.
Interestingly, the sequence of phage and antibiotic administration was found 
to be critical in the overall antibacterial effect from the combination treatment. 
Chaudhry et al. showed the efficiency of removing P. aeruginosa PA14 biofilm was 
higher when the biofilm was treated with phages before antibiotics [85]. A similar 
observation was also reported in another study evaluating phage-antibiotics com-
bination therapy against S. aureus biofilms [86]. However, the observed synergistic 
effects were found to be dependent on the class of antibiotics used. Pre-treatment 
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with phage led to favorable antibacterial effect when combined with linezolid or 
tetracycline, whereas antagonism was observed between the phage and dicloxacillin 
or cefazolin. Furthermore, it is noteworthy that an antagonistic effect was observed 
when the bacterial biofilm was treated with antibiotics preceding the phage therapy, 
irrespective of which class of antibiotics used [86].
6.2 Novel tools for selection of optimum phage-antibiotic combination
Since the exact mechanisms responsible for PAS are still unclear and the choice 
of the combinations is mostly empirical, it is not surprising that mixed results were 
reported in the literature [72, 82]. Also, the concentration of antibiotics used in 
previous studies was limited to one or two levels, which is not enough to predict the 
efficacious concentration when applied in clinical treatment. To solve these prob-
lems, Liu et al. developed a high-throughput platform called synogram by combin-
ing an optically based real-time microtiter plate readout with a matrix-like heat 
map to quickly assess the effects of various phage and antibiotic concentrations on 
bacterial growth [87]. They concluded that PAS is highly dependent on the antibac-
terial mechanism of action for antibiotic and phage pairs and their stoichiometry.
To guide the choice of phage-antibiotic combination, Rodriguez-Gonzalez et al.  
[88] developed an in silico nonlinear population dynamics model taking into 
account the systemic interactions between bacteria, phage and antibiotics to mimic 
in vivo application by given an immune response against bacteria. Using two P. 
aeruginosa strains, one phage-sensitive (resistant to antibiotic) and one antibiotic 
sensitive (resistant to phage), as the model bacteria, the phage-antibiotic combina-
tion therapy was confirmed to outperform the monotherapy. The role of the host 
immune response was also evaluated and the model predicted that the phage-
antibiotic combination failed to eliminate the infection when innate immunity was 
removed or severely reduced. Their findings confirmed the clearance of infection 
is depending on the nonlinear synergistic interactions between phage, antibiotic, 
and innate immunity. The in silico prediction was consistent with previous experi-
mental results obtained in vitro and in vivo. While this model is a valuable tool in 
Figure 2. 
Possible mechanisms responsible for phage-antibiotic synergy.
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identifying potential phage-antibiotic combinations, further modification of the 
model to yield high-resolution temporal data in addition to the final results will be 
useful for quantitative comparison of the model-based predictions with experimen-
tal results.
6.3 Formulations of phage-antibiotic combination to treat lung infections
Streptococcus pneumoniae, S. aureus, B. cepacia complex, Klebsiella pneumonia and 
P. aeruginosa are the major causative pathogens for lung infections. A summary on 
previous work on the combination phage-antibiotic therapy against these pathogens 
were provided in Chang et al. [8]. Recently, Lin et al. screened a panel of antibiotics 
with PEV20 phage to target two P. aeruginosa strains and ciprofloxacin showed the 
highest synergistic effects. The combination was then nebulized using a jet nebu-
lizer and a mesh nebulizer with no difference in the antibacterial effect observed 
between the nebulized samples and non-nebulized suspension [89]. Later, the same 
research team investigated the feasibility of formulating this combination into dry 
powder formulations [90]. PEV20 phage and ciprofloxacin were co-spray dried 
with leucine and with or without lactose. Both formulations maintained bacteri-
cidal synergy after dispersion using a low resistance inhaler or a high resistance 
inhaler, both showing acceptable FPF (60–75%). The antimicrobial efficacy of the 
PEV20-ciprofloxacin combination powder was also confirmed in a mice respiratory 
infection model with significant bacteria reduction (5.9 log) at 24 h post-treatment, 
while no loss of bacteria viability when mice was treated with phage or antibiotics 
alone [91]. The long-term storage stability of the combination powder at 4 °C and 
20% R.H. was also confirmed [92].
7. Challenges for pulmonary delivery of phage and future perspective
Phage therapy is evolving as a promising alternative or an adjuvant to antibiot-
ics for the battle against MDR bacteria. Although a few randomized, double-blind 
and placebo-controlled clinical trials have been conducted to assess tolerance and/
or efficacy of phage therapy in the past few years, none of the completed trials have 
yielded data supporting the promising observations noted in the experimental 
phage therapy conducted in animals and humans. Górski et al. highlighted the 
importance of the quality and titer of the phage preparations and their delivery effi-
ciency to the target sites to ensure a sufficient high phage to bacteria concentration 
in the vicinity of infected tissues [93]. For lung infection, directly delivering phage 
preparation to the airways enhance the incidence of phage getting access to its host 
bacteria, avoiding the rapid clearance in systemic circulation. Advancements have 
been made in the past decade to improve the formulations for pulmonary delivery 
of phage. Here we highlight some hurdles remained to be tackled to bring inhaled 
phage therapy to clinical settings beyond compassionate use and a few prospective 
research directions for the commercial application of aerosol formulations.
As a sufficient amount of phage at the site of infection is the prerequisite for 
successful therapy, nebulizers and DPI are better choice for pulmonary delivery of 
phage compared with pMDI and SMI due to their capacity of high dose delivery. The 
detrimental effect of the various type of nebulizers to phage was found to be phage-
specific, likely attributing to the tail morphology of phage [21] and compositions of 
the phage formulations [18]. Systematic studies to confirm their impacts on phage 
nebulization will provide important information in developing new phage cocktail 
formulations. Although liquid formulations are commonly used for phage therapy, 
solid phage formulations are more desirable for long-term storage and transportation. 
Bacteriophages
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While stable phage powder formulations have been successfully achieved with stor-
age at ambient temperature, they are usually required to be handled and stored at 
low humidity conditions (RH < 20%) [48–50]. These would be easily achievable in 
a manufacturing setting and with pharmaceutical packaging designs. As excessive 
environmental moisture could also be relevant in patients’ homes or in healthcare set-
tings, the impacts of humidity on powdered phage administration should be evaluated 
to ensure the phage product could be used successfully in different geographic regions 
over the world. In preparing phage-powder formulation, trehalose, lactose, and leucine 
are commonly employed to stabilize phage. However, these excipients have not been 
approved for inhalation except lactose was approved as a carrier which is not expected 
to be delivered to the lower respiratory tract. Further in vivo studies are required to 
evaluate the safety profile of these excipients for both short term and long term usage.
Currently, in vivo data of phage therapy for lung infections mostly focused on 
acute infections that phage preparation was given at within a few hours post-infec-
tion. However, in clinical settings, the phages are unlikely given immediately after 
the onset of infection, the postponed treatment may lead to significant bacterial 
growth and biofilm formation, more research is needed to evaluate the thera-
peutic efficacy of phage therapy against chronic lung infection in animal models. 
Moreover, more extensive in vivo PKPD evaluations are needed to investigate the 
optimal administration dose and time for pulmonary phage therapy.
The role of the immune system on phage therapy is largely unexplored in animal 
studies and human trials [33, 88]. Depending on administration route, phage 
type and phage dose, and duration of phage therapy can lead to the generation 
of neutralizing antibodies [94]. Together with increasing evidences showing the 
interactions between phage and mammalian cells [95–97], it would be worthwhile 
to explore the interaction between phage formulations with lung leukocytes and 
epithelial cells lining the alveolar surface and the conducting airways.
Current phage formulation research is largely empirical based. To speed up the 
research progress for phage therapy, in silico models and database would be required 
to predict phage-excipient interaction, phage-antibiotic combination and pharma-
cokinetic/pharmacodynamics (PKPD) profiles.
8. Conclusion
In the past decade, highly acceptable formulations have been achieved with min-
imal phage loss and desirable stability for pulmonary delivery using both nebulizers 
and dry powder inhalers. The synergistic effect of the phage-antibiotic combina-
tion provides an efficient way to prevent the emergence of bacterial resistance and 
reduce the toxicity of antibiotic use. However, systematic PKPD profile of phage 
after administration by inhalation, and the modern tools to accurately predict the 
result of combination therapy are still pending. With the advent of phage research, 
the sound manufacturing and regulatory guidelines towards successful clinical 
trials to bring phage therapy to clinical settings will be beneficial to the patients 
suffering from bacterial infections.
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